Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-04-21

Clinical Trial Update: Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating denosumab to prevent bone loss after teriparatide in premenopausal women with adult idiopathic generalized osteoporosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Denosumab (denosumab)

Snippet

Sponsor: Elizabeth Shane | Conditions: Adult Idiopathic Generalized Osteoporosis | Phase 2 | Status: COMPLETED | Results posted: 2021-04-21